Published in

Bentham Science Publishers, Current Drug Targets, 9(13), p. 1215-1221

DOI: 10.2174/138945012802002357

Bentham Science Publishers, Current Drug Targets, 8(13), p. 1089-1095

DOI: 10.2174/138945012802008982

Links

Tools

Export citation

Search in Google Scholar

TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases

Journal article published in 2012 by Stella Bernardi ORCID, Daniela Milani, Bruno Fabris, Paola Secchiero, Giorgio Zauli
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

This review focuses on TNF-related apoptosis-inducing ligand (TRAIL), also called Apo2 ligand, a protein belonging to the TNF superfamily. TRAIL can be found either in its transmembrane or circulating form, and its mostly studied peripheral effect is the induction of cellular apoptosis. Here, we discuss the evidences supporting the use of TRAIL as biomarker of cardiovascular diseases as well as the evidences showing the potential beneficial therapeutic effects of TRAIL on cardiovascular diseases and diabetes.